P21-Activated Kinase 4 Pak4 Maintains Embryonic Stem Cell Pluripotency via Akt Activation

被引:4
|
作者
Cheng, Fangyuan [1 ,2 ]
Li, Mingyue [1 ,2 ]
Thorne, Rick Francis [3 ,4 ]
Liu, Guangzhi [4 ]
Yuwei, Zhang [4 ]
Wu, Mian [1 ,2 ,3 ,4 ]
Liu, Lianxin [1 ,2 ]
机构
[1] Univ Sci & Technol China, Affiliated Hosp 1, Div Life Sci & Med, Hefei 230027, Anhui, Peoples R China
[2] CAS Ctr Excellence Mol Cell Sci, Innovat Ctr Cell Signaling Network, Hefei 230027, Anhui, Peoples R China
[3] Zhengzhou Univ, Henan Prov Peoples Hosp, Acad Med Sci, Translat Res Inst, Zhengzhou, Henan, Peoples R China
[4] Henan Univ, Henan Prov Peoples Hosp, Henan Key Lab Stem Cell Differentiat & Modificat, Zhengzhou, Henan, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
Pak4; Nanog; Akt; pluripotency; induced pluripotent stem cells (iPSCs); murine embryonic stem cells (mESCs); SELF-RENEWAL; TRANSCRIPTION FACTOR; GROUND-STATE; CANCER CELLS; MOUSE; DIFFERENTIATION; EXPRESSION; NANOG; PROLIFERATION; MAINTENANCE;
D O I
10.1093/stmcls/sxac050
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Exploiting the pluripotent properties of embryonic stem cells (ESCs) holds great promise for regenerative medicine. Nevertheless, directing ESC differentiation into specialized cell lineages requires intricate control governed by both intrinsic and extrinsic factors along with the actions of specific signaling networks. Here, we reveal the involvement of the p21-activated kinase 4 (Pak4), a serine/threonine kinase, in sustaining murine ESC (mESC) pluripotency. Pak4 is highly expressed in R1 ESC cells compared with embryonic fibroblast cells and its expression is progressively decreased during differentiation. Manipulations using knockdown and overexpression demonstrated a positive relationship between Pak4 expression and the clonogenic potential of mESCs. Moreover, ectopic Pak4 expression increases reprogramming efficiency of Oct4-Klf4-Sox2-Myc-induced pluripotent stem cells (iPSCs) whereas Pak4-knockdown iPSCs were largely incapable of generating teratomas containing mesodermal, ectodermal and endodermal tissues, indicative of a failure in differentiation. We further establish that Pak4 expression in mESCs is transcriptionally driven by the core pluripotency factor Nanog which recognizes specific binding motifs in the Pak4 proximal promoter region. In turn, the increased levels of Pak4 in mESCs fundamentally act as an upstream activator of the Akt pathway. Pak4 directly binds to and phosphorylates Akt at Ser473 with the resulting Akt activation shown to attenuate downstream GSK3 beta signaling. Thus, our findings indicate that the Nanog-Pak4-Akt signaling axis is essential for maintaining mESC self-renewal potential with further importance shown during somatic cell reprogramming where Pak4 appears indispensable for multi-lineage specification.
引用
收藏
页码:892 / 905
页数:14
相关论文
共 50 条
  • [21] p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling
    Tyagi, Nikhil
    Marimuthu, Saravanakumar
    Bhardwaj, Arun
    Deshmukh, Sachin K.
    Srivastava, Sanjeev K.
    Singh, Ajay P.
    McClellan, Steven
    Carter, James E.
    Singh, Seema
    CANCER LETTERS, 2016, 370 (02) : 260 - 267
  • [22] P21-activated kinase 4-Not just one of the PAK
    Dart, Anna E.
    Wells, Claire M.
    EUROPEAN JOURNAL OF CELL BIOLOGY, 2013, 92 (4-5) : 129 - 138
  • [23] Loss of p21-activated kinase Mbt/PAK4 causes Parkinson-like phenotypes in Drosophila
    Puetz, Stephanie M.
    Kram, Jette
    Rauh, Elisa
    Kaiser, Sophie
    Toews, Romy
    Lueningschroer-Wang, Yi
    Rieger, Dirk
    Raabe, Thomas
    DISEASE MODELS & MECHANISMS, 2021, 14 (06)
  • [24] INHIBITION OF P21-ACTIVATED KINASE 4 (PAK4) REVERTS IMMUNE EXCLUSION AND RESTORES ANTITUMOR IMMUNITY IN THE TUMOR MICROENVIRONMENT
    Zhou, Yu 'Jerry'
    Chu, Gina
    Hendrickson, Eleanore
    Gullo-Brown, Johnni
    Chavez, Brandy
    McAlpine, Indrawan
    Rui, Eugene
    Doran, Shawn
    Timofeevski, Sergei
    Heyen, Jonathan
    Kinong, Jennifer
    Tang, Szu-Yu
    Oyer, Jon
    Rayannavar, Vinayak
    Nager, Andrew
    Ching, Keith
    Shi, Stephanie
    Bhadra, Rajarshi
    Dillon, Christopher
    Gururajan, Murali
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A768 - A768
  • [25] PRESENCE OF THE P21-ACTIVATED KINASE, PAK4, IN PANCREATIC ACINAR CELLS AND ITS ACTIVATION BY NUMEROUS GASTROINTESTINAL HORMONES AND GROWTH FACTORS
    Ramos, Irene
    Nuche-Berenguer, Bernardo
    Moreno, Paola
    Mantey, Samuel A.
    Iordanskaia, Tatiana
    Jensen, Robert T.
    GASTROENTEROLOGY, 2017, 152 (05) : S902 - S902
  • [26] Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma
    Aboukameel, Amro
    Muqbil, Irfana
    Senapedis, William
    Baloglu, Erkan
    Landesman, Yosef
    Shacham, Sharon
    Kauffman, Michael
    Philip, Philip A.
    Mohammad, Ramzi M.
    Azmi, Asfar S.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (01) : 76 - 87
  • [27] Molecular basis for integrin adhesion receptor binding to p21-activated kinase 4 (PAK4) (vol 5, 1257, 2022)
    Ha, Byung Hak
    Yigit, Sezin
    Natarajan, Nalini
    Morse, Elizabeth M.
    Calderwood, David A.
    Boggon, Titus J.
    COMMUNICATIONS BIOLOGY, 2023, 6 (01)
  • [28] Zinc Maintains Embryonic Stem Cell Pluripotency and Multilineage Differentiation Potential via AKT Activation
    Mnatsakanyan, Hayk
    Sabater i Serra, Roser
    Salmeron-Sanchez, Manuel
    Rico, Patricia
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2019, 7
  • [29] Design, synthesis and biological evaluation of 1-phenanthryl-tetrahydroisoquinoline derivatives as novel p21-activated kinase 4 (PAK4) inhibitors
    Song, Shuai
    Li, Xiaodong
    Guo, Jing
    Hao, Chenzhou
    Feng, Yan
    Guo, Bingyu
    Liu, Tongchao
    Zhang, Qiaoling
    Zhang, Zhen
    Li, Ruijuan
    Wang, Jian
    Lin, Bin
    Li, Feng
    Zhao, Dongmei
    Cheng, Maosheng
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2015, 13 (12) : 3803 - 3818
  • [30] Characterization of in vitro activity and predictive biomarkers of the novel p21-activated kinase 4 (PAK4) inhibitor, PF-3758309, in colorectal cancer cell lines
    Kulikowski, Gillian N.
    Pitts, Todd M.
    Tan, Aik Choon
    Tentler, John J.
    Britt, Blair C.
    Britt, Byron W.
    Murray, Brion W.
    Carley, William
    Smeal, Tod
    Guo, Chuangxing
    Eckhardt, S. Gail
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)